Psoriasis comorbidity management in the COVID era: a pressing challenge
An Erratum on
Psoriasis comorbidity management in the COVID era: a pressing challenge
by Song, Y., Yao, L., Li, S., and Zhou, J. (2023). Front. Microbiol. 14:1294056. doi: 10.3389/fmicb.2023.1294056
Due to a production error, there was an error in affiliation 1. Instead of “Department of Dermatology, Hospital of Jilin University, Changchun, China”, it should be “Department of Dermatology, First Hospital of Jilin University, Changchun, China”.
The publisher apologizes for this mistake. The original version of this article has been updated.
Keywords: COVID-19, SARS-CoV-2, psoriasis, comorbidity, management, biologics
Citation: Frontiers Production Office (2024) Erratum: Psoriasis comorbidity management in the COVID era: a pressing challenge. Front. Microbiol. 15:1502059. doi: 10.3389/fmicb.2024.1502059
Received: 26 September 2024; Accepted: 26 September 2024;
Published: 04 October 2024.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2024 Frontiers Production Office. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Frontiers Production Office, cHJvZHVjdGlvbi5vZmZpY2UmI3gwMDA0MDtmcm9udGllcnNpbi5vcmc=